UI Hospitals and Clinics

Studies | Researchers

Clinical Research

Showing newest first. Show oldest first. Or order by title

  1. A Randomized Phase II Study of NCI Supplied Cabozantinib (NSC #761968 IND #116059) versus weekly paclitaxel (NSC #673089) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube…
    David Bender
  2. A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects with Refractory Chronic Lymphocytic Leukemia
    Thomas Carter
  3. A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination with Continuous or Intermittent CTEP-Supplied Agent ABT-888 (NSC #737664, I…
    David Bender
  4. A Pilot Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcoma (40)
    Mohammed Milhem
  5. An Open-Label, Multicenter, Randomized, Phase III Study to Investigate the Efficacy and Safety of Bendamustine Compared with Bendamustine + RO5072759 (GA101) in Patients with Rituximab-Refractory, Ind…
    Brian Link
  6. Cytogenetic Studies in Acute Leukemia
    Daniel Vaena
  7. A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemo-Naïve Sex Cord-Stromal Tumors of the Ovary
    David Bender
  8. Umbrella Long-Term Follow-Up Protocol
    Ayman El-Sheikh
  9. Defibrotide for Patients with Hepatic Veno-Occlusive Disease (VOD): A Treatment IND Study (Under CFR 312.34)
    Margarida Magalhaes-Silverman
  10. Treatment to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
    Ayman El-Sheikh
  11. A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded t…
    Thomas Carter
  12. A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib (IND#114480; NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD
    Ayman El-Sheikh
  13. A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients with Cystic Fibrosis Treated with Pancreatic Enzyme Replacement Therapy…
    Richard Ahrens
  14. Treatment of Patients with Newly Diagnosed Standard Risk Lymphoblastic Leukemia (B-ALL) or localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
    Ayman El-Sheikh
  15. A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carci…
    David Bender
  16. Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
    Nancy Sharma
  17. Assessing Nasopharyngeal and Pulmonary Adverse Events that may be Associated Certain Medications
    Linda Cadaret
  18. A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study to Evaluate the Pharmacodynamics, Efficacy and Safety of RM-131 Administered to Patients with Parkinson’s…
    Ergun Uc
  19. Phase Ib/II Study of ALT-801with Cisplatin in Patients with Metastatic Melanoma
    Mohammed Milhem
  20. Adolescent Brain Development - History
    Daniel O'Leary

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.